Tigecycline(tye gah sigh’ klin)
Tygacil
PREGNANCY CATEGORY D
Drug Classes
Antibiotic
Glycylcycline
Therapeutic Actions
Inhibits protein translation on ribosomes in specific bacteria, leading to inhibition of bacterial cell growth and cell death; mechanism is not used by many resistant strains.
Indications
Treatment of complicated skin and skin structure infections caused by susceptible strains of Escherichia coli, Enterococcus faecalis (vancomycin-susceptible strains only), Staphylococcus aureus (methicillin-susceptible and resistant strains), Streptococcus agalactiae, Streptococcus anginosus, Streptococcus pyogenes, Bacteroides fragilis, Klebsiella pneumoniae, Enterobacter cloacae
Treatment of adults with community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Legionella pneumophila
Treatment of intra-abdominal infections caused by Citrobacter freundii, Enterobacter cloacae, E. coli, Klebsiella oxytoca, Klebiella pneumoniae, Enteroccus faecalis (vancomycin susceptible strains only), S. anginosus, B. fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, Peptostreptococcus micros
Unlabeled use: Hospital-acquired pneumonia
Contraindications and Cautions
Contraindicated with hypersensitivity to tigecycline or any of its components, pregnancy.
Use cautiously with allergy to tetracycline antibiotics, lactation.
Available Forms
Powder for reconstitution for injection—50 mg/5 mL vial
Dosages
Adults
100 mg IV, followed by 50 mg IV every 12 hr. Tygacil should be infused over 30–60 min. Therapy should continue for 5–14 days, based on patient response and bacterial progress.
Patients with severe hepatic impairment (Child-Pugh C)
100 mg IV, followed by 25 mg IV every 12 hr. Patient should be monitored closely.
